

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 July 2011 (14.07.2011)

(10) International Publication Number  
**WO 2011/083076 A1**

(51) International Patent Classification:  
*C12N 15/10* (2006.01)    *C12N 1/06* (2006.01)  
*C12Q 1/68* (2006.01)

(21) International Application Number:  
PCT/EP2011/000013

(22) International Filing Date:  
5 January 2011 (05.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
12/684,762    8 January 2010 (08.01.2010)    US

(71) Applicant (for DE only): **ROCHE DIAGNOSTICS GMBH** [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors: **JOHNSON, Jenny, A.**; 21105 Dawe Avenue, Castro Valley, CA 94546 (US). **KYGER, Erich**; 1756 Sanker Peak Way, Antioch, CA 94531 (US).

(74) Common Representative: **ROCHE DIAGNOSTICS GMBH**; Patent Department, 68298 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

**Published:**

— with international search report (Art. 21(3))

**WO 2011/083076 A1**

(54) **Title:** IMPROVED RECOVERY OF NUCLEIC ACIDS FROM MAGNETIC GLASS PARTICLES

(57) **Abstract:** The present invention is a method of separating nucleic acids using a solid phase capable of binding nucleic acids, such as magnetic glass particles, where binding of nucleic acids to the solid phase is enhanced by the presence of an ethylene-amine compound. The invention further includes a reaction mixture for isolating nucleic acids containing an ethylene-amine compound and kits for carrying out the method.

## IMPROVED RECOVERY OF NUCLEIC ACIDS FROM MAGNETIC GLASS PARTICLES

## FIELD OF THE INVENTION

5 The invention relates to the field of isolating nucleic acids and specifically, to the field of isolating nucleic acids using solid supports.

## BACKGROUND OF THE INVENTION

10 Isolation of nucleic acids is an important step in molecular diagnostics. The quality and quantity of nucleic acids isolated from a sample greatly affects the success of downstream diagnostic applications. The clinical and field applications also demand that the isolation procedure be quick and amenable to automation.

15 Many procedures exist for isolating nucleic acids from various organisms and tissues. Some types of clinical and environmental samples present special challenges to successful isolation of nucleic acids. For example, certain tissues such as bone contain large amount of extracellular material that require removal before nucleic acids can be accessed. Some organisms, such as fungi, plants and bacteria possess cell walls or outer membranes that require harsh chemical treatment. The reagents used in the harsh treatments pose challenges for the downstream applications that utilize the isolated nucleic acids. Furthermore, degradation of the target nucleic acids during harsh treatment may lead to a 20 false-negative result in the downstream detection assay. Yet to be clinically acceptable, a diagnostic procedure must have sufficient sensitivity, i.e. avoid false-negative results in patients' samples. Therefore in the field of molecular diagnostics, there is a need for improvement of the methods of isolating nucleic acids in order to make the diagnostic procedures sensitive, reliable and easy to perform.

25 A prerequisite for successful nucleic-acid based diagnostic test is isolation of undegraded, inhibitor-free nucleic acids. At the same time, there is a demand for simple, automation-friendly nucleic acid isolation procedures. Recently it has become popular to isolate nucleic acids using solid supports, such as for example, spherical microparticles. Especially popular

are magnetic microparticles containing or coated with a glass-like substance, commonly referred to as "Magnetic Glass Particles" or "MGPs." The nucleic acids isolation procedures employing MGPs require comparatively few steps and are easily automated. Especially popular are MGPs made by the sol-gel method, described in European publication EP 1 154 5 443 or U.S. Patents 6,255,477 and 6,870,047.

The general descriptions and specific examples of MGPs made by the sol-gel method are readily available in the literature (see e.g. EP 1 154 443). These MGPs consist of a ferromagnetic core coated with silica-based glass-like material. The ferromagnetic core typically contains iron oxides, e.g.  $Fe_3O_4$  or  $Fe_2O_3$ . The core may be a simple iron core, or 10 may be made of a composite material. The core can also consist of a crystalline, ceramic or glass-like structure in which iron oxide is embedded. The glass coating may consist of amorphous material containing silicon oxide and further may contain one or more additional metal oxides such as boron oxide ( $B_2O_3$ ), aluminum oxide ( $Al_2O_3$ ), calcium oxide ( $CaO$ ), barium oxide ( $BaO$ ), potassium oxide ( $K_2O$ ), sodium oxide ( $Na_2O$ ), 15 magnesium oxide ( $MgO$ ) or lead oxide ( $Pb_2O_3$ ). In some embodiments, the glass is silicon oxide and also contains one or more compounds in the following concentration range:  $B_2O_3$  (0-30%),  $Al_2O_3$  (0-20%),  $CaO$  (0-20%),  $BaO$  (0-10%),  $K_2O$  (0-20%),  $Na_2O$  (0-20%),  $MgO$  (0-18%),  $Pb_2O_3$  (0-15%). The glass may also contain a smaller percentage (0-5%) of a number of other oxides such as  $Mn_2O_3$ ,  $TiO_2$ ,  $As_2O_3$ ,  $Fe_2O_3$ ,  $CuO$  and  $CoO$ . Surfaces made 20 of a composition of borosilicate glass have proven to be especially effective. Borosilicate glasses have a boron oxide content of more than 25%, e.g. a 70/30 composition of  $SiO_2/B_2O_3$ .

The magnetic particles are sometimes modified with functional groups that facilitate the binding of nucleic acids. Such groups include, without limitation, poly-T oligonucleotides, 25 for the capture of poly-A-containing nucleic acids, streptavidin, for the capture of biotin-labeled nucleic acids and specific probe sequences for the capture of nucleic acids containing the unique sequence complementary to the probe. However, most universally useful are magnetic particles with unmodified surfaces that are capable of isolating any nucleic acid present in the sample, regardless of the sequence.

30 A typical nucleic acid isolation protocol using MGPs commences with disruption of the cells or tissues in order to release the nucleic acids. The commonly used tissue disruption

procedures are of chemical, enzymatic or physical nature, including ultrasound, high pressure, shear forces, strong bases, detergents or chaotropic agents, proteases or lipases. For chemical and enzymatic lysis, the lysis reagent typically includes a buffering agent, a salt, one or more of a denaturing substance and a chaotropic substance, a protease and 5 optionally, a nuclease inhibitor and a preservative. The lysis reagent causes digestion of proteins, inhibition of nucleases, and solubilization of lipids, lipoproteins, and the like. For example, the buffering agent may be Tris, the salt may be a sodium, a potassium, an ammonium or a magnesium salt, such as a chloride or an acetate, the detergent may be sodium dodecyl sulfate, Triton-X or Tween, the chaotropic reagent may be urea, thio-urea, 10 sodium iodite, sodium dodecyl sulfate, sodium perchlorate, guanidinium thiocyanate, guanidinium isothiocyanate or guanidinium hydrochlorite, the nuclease inhibitor may be a chelator such as EDTA, the preservative may be a metal azide, and the protease may be proteinase K. Typically, the sample is incubated with the lysis reagent at temperatures between 70 and 100°C, e.g., 90 - 95°C.

15 For most samples, the lysis reagents and conditions described above are sufficient to achieve the lysis of the cells and release nucleic acids into solution. Unfortunately, for some types of samples, lysis poses a major challenge. Some cells, organisms and tissues require harsh lysis conditions in order to break up the cell wall or tissue and release cellular contents. For example, Gram-positive pathogens such as *Mycobacterium tuberculosis* have lipid-rich 20 peptidoglycan cell walls. There is a world-wide need for rapid methods of detecting *M. tuberculosis* and other mycobacteria. However, nucleic acid isolation is often a limiting factor for reaching desirable levels of assay sensitivity. See Neonakis et al. (2008) Molecular diagnostic tools in mycobacteriology, *J. Microbiol. Methods*, 75:111. Currently the desired sensitivity in a mycobacteria detection assay is achieved with a multi-step nucleic acid 25 isolation procedure that includes repeated wash and centrifugation steps. See Shampauta et al. (2004) Molecular genetic methods for diagnosis and antibiotic resistance detection of mycobacteria from clinical specimens, *APMIS*, 122:728. Such procedure however is not automatable and not practical for most users.

30 In a typical method of isolating nucleic acids using MGPs, after the cellular compartments in the sample have been broken up to release the nucleic acids, the sample is brought into contact with MGPs in order to achieve binding of the nucleic acids to the MGPs. The MGPs may be added to the sample prior to lysis. For example, MGPs can be present in the

vessel to which the initial sample is added. It has been found that the presence of MGPs does not affect lysis of the sample. Alternatively, the sample may be lysed first and MGPs introduced only after the lysis step is complete.

To achieve binding to MGPs, the sample is typically mixed with MGPs and incubated in this binding mixture for a period of time sufficient for the binding to occur. This step can be easily optimized by determining the quantity of immobilized nucleic acids on the surface of the magnetic glass particles at different points in time or by determining the yield of nucleic acids following different incubation times. Generally, incubation times of between 10 seconds and 30 minutes are appropriate for nucleic acids.

10 In most instances, the lysis reagent containing released nucleic acids is a suitable environment for the binding to MGPs to occur. However, in some instances, the lysis reagent makes the environment unsuitable for the binding of nucleic acids to the surface of magnetic glass particles. Especially where magnetic glass particles have unmodified surface, the binding between nucleic acids and the surface of the particles is dependent on 15 conditions such as pH and ionic strength of the binding mixture. It has been found that maximum binding of nucleic acids to MGPs occurs at low pH, such as pH 5 or lower. However, for some applications, such low pH of the binding mixture may not be achieved. For example, the lysis reagent for lysing mycobacteria has a pH value of 12 or higher. In a typical procedure for isolating mycobacterial nucleic acids, the pH is lowered during a 20 neutralization step following cell lysis but to not less than pH 9. At pH 9 or higher, the binding of nucleic acids to magnetic glass particles is inefficient. Up to the present time, this inefficiency of binding has been overcome by prolonged incubation times. This way of solving the problem is impractical for clinical applications. Furthermore, prolonged incubation threatens stability of the nucleic acid templates especially RNA templates.

25

## SUMMARY OF THE INVENTION

The present invention is a method of separating nucleic acids from a sample solution containing nucleic acids, comprising contacting the sample solution with a solid phase capable of binding nucleic acids and a binding mixture comprising an ethylene-amine

30 compound; incubating the sample solution containing the solid phase under the conditions

in which the nucleic acids may bind to the solid phase; and separating the solid phase from the solution. The method optionally includes a step of washing the bound nucleic acids prior to elution. In some embodiments, the method includes detecting the nucleic acids after isolation. The invention further includes a reaction mixture for isolating nucleic acids, 5 the mixture containing a solid phase capable of binding nucleic acids and an ethylene-amine compound. The invention also includes a kit for separating nucleic acids from a sample using solid phase the kit comprising: a solid phase capable of binding nucleic acids and an ethylene-amine compound.

## 10 DETAILED DESCRIPTION OF THE INVENTION

### *Definitions*

As used herein, the term "ethylene-amine compound" refers to a molecule having a general formula  $(\text{NH}_2\text{-CH}_2=\text{CH}_2)_n\text{-NH}_2$ , wherein n is 1-10 or more. Ethylene-amine compounds useful in the present invention include, but are not limited to, ethylene-diamine (EDA), 15 diethylene-triamine (DETA), triethylene-tetramine (TETA), tetraethylene-pentamine (TEPA) and pentaethylene-hexamine (PEHA). One of skill in the art will appreciate that other ethylene-amine compounds are useful in the present invention.

As used herein, the term "sample" refers to a mixture or solution containing the substance of interest, e.g. a nucleic acid. The sample may comprise a solid or liquid tissue, a body 20 fluid, a culture or suspension of eukaryotic cells (including plant, fungal, animal or human cells), a culture or suspension of prokaryotic cells (including bacterial cells). The sample may comprise viruses. The sample may also comprise a cell-free solution containing a substance of interest. Depending on the nature of the sample, it may require chemical or physical treatment to facilitate isolation of the substance of interest from the sample. For 25 example, the sample may require treatment to release nucleic acids from cellular and subcellular compartments.

As used herein, the term "component" of a biological sample refers to a class of molecules (e.g., proteins, nucleic acids, etc.) or a specific target such as a specific protein or nucleic acid sequence that one wishes to detect.

As used herein, the term "nucleic acid" refers to polymers of deoxyribonucleotides (containing 2-deoxy-D-ribose) (i.e., DNA), polyribonucleotides (containing D-ribose) (i.e., RNA), and any other N-glycoside analogs of a purine or pyrimidine base, or modified purine or pyrimidine bases, or a combination thereof.

5 In the method of the present invention, the nucleic acids are isolated from a sample using magnetic glass particles, wherein the binding of the nucleic acids to the magnetic glass particles is enhanced by the presence of one or more ethylene-amine compounds.

In some embodiments, the sample contains whole cells. The cells are lysed using a lysis reagent suitable for disrupting the cellular membranes and, if present, cell walls in order to 10 release the nucleic acids from the cellular and subcellular compartments. Various methods of disrupting cells and tissues are known in the art. Many methods are referenced and described in Sambrook & Russell, *Molecular Cloning, A Laboratory Manual* (3rd Ed, 2001)).

In some embodiments, the sample contains Gram-positive bacteria. The Gram-positive bacteria are lysed using a lysis reagent comprising a strong chemical base (e.g. alkali 15 hydroxide), a detergent and a salt and having pH greater than 12. In some embodiments, the sample containing Gram-positive bacteria is heated to between 80°C and 100°C, usually about 95°C and incubated for between 5 and 30 minutes, usually about 15 minutes.

According to the present invention, the sample containing nucleic acids free from cellular and subcellular compartments is brought in contact with magnetic glass particles under 20 conditions suitable for the binding of nucleic acids to the magnetic glass particles. It has been discovered that the addition of ethylene-amine compounds to the binding mixture greatly increases the efficiency of binding of nucleic acids to the surface of magnetic glass particles. This phenomenon is especially beneficial at high pH. The efficiency of binding is further increased by the presence of metal salts, for example, magnesium or manganese salts, 25 such as chloride or acetate salts, in the binding mixture.

In some embodiments, the concentration of ethylene-amine compounds is between 10 and 65 mM, e.g., 16 mM.

Following the binding step, the magnetic glass particles with bound nucleic acids can be separated from the solution containing ethylene-amine compounds. Depending on the size

and type of magnetic glass particles, the particles either separate out of the fluid during the incubation period, or remain in suspension after the incubation and require further separation. If a separation step is required, the particles with bound nucleic acids are separated from the sample solution by application of a magnetic field. For instance, the 5 magnetic glass particles can be pulled to the wall or the bottom of the sample vessel in which the incubation was performed. The liquid containing any unbound substances and contaminants present in the sample can then be removed from the sample vessel via pipetting or aspiration.

The magnetic glass particles with bound nucleic acids may optionally be washed one or 10 more times with one or more wash solutions. A wash solution has a composition that does not cause the nucleic acids to be released from the particle surface, but that washes away the undesired contaminants still associated with the nucleic acids or magnetic glass particles. In some embodiments, the initial wash solution contains alcohol, for example ethanol or isopropanol. The wash solution may also contain a chaotropic salt and a buffer. In some 15 embodiments, the subsequent wash solution is alcohol-free, but contains a salt, a buffer and optionally, a preservative. This wash step may take place by incubating the wash solution with magnetic glass particles to which nucleic acids are bound. The particles may be resuspended during this step to achieve maximum contact with the washing fluid. The contaminated wash solution is then removed from the sample vessel.

20 After the last wash step, the magnetic glass particles with bound nucleic acids may be dried briefly in a vacuum, or the residual wash fluid may be allowed to evaporate. If desired, nucleic acids can be separated from the magnetic particles and optionally removed from the vessel containing the magnetic particles, leaving the particles behind. Nucleic acids may be eluted from the magnetic glass particles using a buffer having a low salt content. In some 25 embodiments, the elution buffer contains Tris. Optionally, the elution buffer may contain preservatives and nuclease inhibitors, for example chelators such as EDTA. In other embodiments, the elution buffer is water with or without preservatives.

In some embodiments, nucleic acids may remain bound to the magnetic particles during downstream applications. (See e.g. U.S. Application Publication No. 20040014070). In 30 other embodiments, nucleic acids are dislodged from the magnetic glass particles, but the particles remain in the vessel with nucleic acids for downstream applications. For example,

the publication US20040014070 teaches that magnetic glass particles made by the sol-gel method improve the efficiency of amplification of nucleic acids by PCR. In other instances, the nucleic acids may be separated from the magnetic glass particles after elution. Typically, the solution containing nucleic acids is removed from the vessel containing the magnetic  
5 glass particles.

In some embodiments, the method of isolation of nucleic acids further includes amplification and detection of the isolated target nucleic acids. For example, the amplification and detection are performed using PCR, see *Principles and Applications for DNA Amplification* (ed. H. A. Erlich, Freeman Press, New York, N.Y., 1992); *PCR*  
10 *Protocols: A Guide to Methods and Applications* (eds. Innis, et al., Academic Press, San Diego, Calif., 1990). The amplification and detection may also be performed via the ligase chain reaction (LCR) (U.S. Patent Nos. 5,185,243, 5,679,524 and 5,573,907) or any other suitable nucleic acid amplification technology. While any downstream analysis method is compatible with the isolation method of the present invention, the composition of the lysis  
15 solution and the binding solution according to the present invention are especially compatible with the downstream PCR application.

In a real-time PCR assay, the signal generated by the labeled probe is proportional to the amount of input target nucleic acid. The greater the input, the earlier the fluorescence signal crosses a predetermined threshold value ( $C_t$ ). Therefore one can determine relative  
20 or absolute amounts of the target nucleic acid by comparing the samples to each other or to a control sample with a known amount of nucleic acid.

In another embodiment, the invention is a reaction mixture for isolating nucleic acids. The reaction mixture may contain a lysis reagent, the reagent comprising one or more detergents, an ethylene-amine compound and optionally, a metal salt such as, for example,  
25 a magnesium or a manganese salt, one or more preservatives, and/or one or more chelators. In some embodiments, the lysis reagent has a pH value of 12 or more. In some embodiments, the lysis reagent in the reaction mixture comprises one or more detergents at a concentration of 1-10%, one or more chelators such as EDTA at a concentration of 0.5-2 mM, one or more preservatives, such as sodium azide at a concentration of 0.01-0.1%, an ethylene-amine compound at a concentration of 10-65 mM and a metal salt, such as  
30

magnesium or manganese salt, such as a chloride or an acetate at a concentration of 5-25 mM.

In some embodiments, the reaction mixture further contains a sample including nucleic acids to be isolated. In some instances, the sample contains lysed Gram-positive bacteria as 5 the source of nucleic acid. In yet other embodiments, the reaction mixture contains magnetic glass particles. In some instances the particles are manufactured by the sol-gel method described in the U.S. Patent 6,870,047 and references cited therein.

In yet another embodiment, the invention is a kit for isolating nucleic acids using magnetic glass particles. The kit includes a lysis reagent, the reagent comprising one or more

10 detergents, and optionally, one or more preservatives, an ethylene-amine compound and optionally, a magnesium or manganese salt. In some embodiments, the lysis reagent, the ethylene-amine compound and the magnesium or manganese salt are provided in separate containers. In some embodiments, the lysis reagent may have a pH value of 12 or more. In some embodiments, the lysis reagent included in the kit comprises one or more detergents 15 at a concentration between 1-10%, one or more chelators such as EDTA at a concentration between 0.5-2 mM, one or more preservatives, such as sodium azide at a concentration between 0.01-0.1%, an ethylene-amine compound at a concentration between 10-65 mM and a magnesium or manganese salt, such as magnesium chloride or manganese acetate at a concentration between 5-25 mM. The kit may further include magnetic glass particles.

20 Magnetic glass particles may be incorporated into a lysis reagent or present in a separate container in the kit. When magnetic glass particles are present in a separate vessel, the particles may be suspended in alcohol such as isopropanol. In some instances, the magnetic particles included in the kit of the present invention are manufactured by the sol-gel method described in the U.S. Patent 6,870,047 and references cited therein. In some

25 embodiments the kit optionally includes a neutralization reagent, a wash reagent and an elution reagent. The neutralization reagent may contain a buffer, a salt and a preservative and have a pH between 6 and 8, most preferably pH 7.5. In some embodiments, the buffer may be Tris, the salt may be magnesium chloride and the preservative may be sodium azide. The wash reagent may contain alcohol. The elution reagent may contain a buffer and a

30 preservative and have a pH of 8.5.

## EXAMPLES

As an illustration only and not to limit the scope of the invention, the method was applied to isolation of nucleic acids from *Mycobacterium tuberculosis* (MTB).

*EXAMPLE 1:*

5 For lysis, the sample comprising 100  $\mu$ L of a *Mycobacterium tuberculosis* (MTB) cell suspension or the same volume of MTB DNA in 67 mM phosphate pH 6.8 was combined with 400  $\mu$ L of lysis reagent (50 mM NaOH, 1% Triton X-100, 1 mM EDTA, 0.05% NaN<sub>3</sub>, pH 12+) and incubated for 15 minutes at 95°C. Then 400  $\mu$ L of neutralization reagent was added (8-64 mM ethylene-amine, 200 mM Tris, 8-23 mM MgCl<sub>2</sub> or Mg(OAc)<sub>2</sub> 0.05% NaN<sub>3</sub>, pH 7.5). Then 100uL of magnetic glass particles (Roche Molecular Systems, Inc., Branchburg, N.J.) were added and the sample incubated for 5-30 min at room temperature or at 37°C. The magnetic glass particles were then separated by removing the supernatant, and washed twice with 7.5 mM sodium citrate dihydrate, 0.05% (w/v) MIT, pH 4.1. The nucleic acids were eluted with 50-100  $\mu$ L elution reagent (30 mM Tris, pH 8.5, 0.2% w/v 10 methyl-4-hydroxybenzoate (methyl paraben), 0.09% NaN<sub>3</sub>). The post-lysis procedures 15 were performed either manually or automatically by the Hamilton Star instrument (Hamilton Robotics, Inc., Reno, Nev.).

The isolated nucleic acid was tested by quantitative PCR also known as real-time PCR. The PCR was performed with 50  $\mu$ L of eluate and 50  $\mu$ L of master mix comprising 154 mM 20 Tricine, 110 mM potassium hydroxide, 190 mM potassium acetate, 19% glycerol (v/v), 2.3% DMSO, 1.16 mM dATP, 1.16 mM dCTP, 1.16 mM dGTP, 1.16 mM dUTP, upstream and downstream primer, target probe, internal control probe, DNA polymerase, uracil-N-DNA glycosylase, 0.09% sodium azide (w/v), pH 8.50, and 20 copies/reaction of internal 25 control DNA. The amplification conditions on the COBAS® TAQMAN® 48 Analyzer were: 5 min at 50°C followed by two cycles of 98°C for 20 sec, 61°C sec, and 70°C sec, then 55 cycles of 95°C for 25 sec, 61°C for 40sec, and 70°C for 20sec.

The results are expressed as the “cycles-to-threshold” (C<sub>t</sub>) value (a cycle number at which 30 the fluorescence from a sample exceeds the background fluorescence and thus “crosses the threshold”). C<sub>t</sub> is reflective of the starting amount of the nucleic acid template. A lower C<sub>t</sub> value indicates a greater starting amount of the nucleic acid template in the reaction, while a

higher  $C_t$  value indicates a lower starting amount of the nucleic acid template in the reaction. Tables 1-3 show  $C_t$  values for each PCR reaction containing nucleic acids isolated using the method of the present invention.

*Table 1*

5 *Nucleic acid recovery from whole MTB aided by an ethylene-amine and a metal salt*

[TETA*] mM	Ct	Std Dev (n=2)
8	37.0	1.24
16	36.4	0.55
32	36.1	0.42
64	37.0	0.05

[TETA] mM/ [MgCl <sub>2</sub> ] mM	Ct	Std Dev (n=2)
0,0	38.8	0.35
8,10	36.6	0.22
16,15	36.3	0.12
32,15	36.7	0.61

\*TETA – Triethylenetetramine

*Table 2*

*Nucleic acid recovery from whole MTB aided by various ethylene-amines and a metal salt*

No.	Additives	RT Binding		37°C Binding	
		Ct	Std Dev (n=3)	Ct	Std Dev (n=3)
1	8mM MgCl <sub>2</sub>	29.70	0.05	29.42	0.12
2	8mM MgCl <sub>2</sub> + 16mM EDA*	30.16	0.33	29.65	0.05
3	8mM MgCl <sub>2</sub> + 16mM DETA	29.02	0.05	28.96	0.17
4	8mM MgCl <sub>2</sub> + 16mM TETA	28.61	0.03	28.28	0.17
5	8mM MgCl <sub>2</sub> + 16mM TEPA	28.37	0.19	28.29	0.09
6	8mM MgCl <sub>2</sub> + 16mM PEHA	31.46	0.30	31.57	0.30

No.	Additives	RT Binding		37°C Binding	
		Ct	Std Dev (n=3)	Ct	Std Dev (n=3)
1	23mM MgCl <sub>2</sub>	30.62	0.23	31.11	0.40
2	23mM MgCl <sub>2</sub> + 16mM EDA	30.30	0.27	30.40	0.31
3	23mM MgCl <sub>2</sub> + 16mM DETA	28.47	0.06	28.77	0.22
4	23mM MgCl <sub>2</sub> + 16mM TETA	28.33	0.19	28.31	0.41
5	23mM MgCl <sub>2</sub> + 16mM TEPA	28.57	0.14	28.59	0.10
6	23mM MgCl <sub>2</sub> + 16mM PEHA	31.78	1.10	29.96	0.59

\*EDA – Ethylenediamine; DETA – Diethylenetriamine; TETA – Triethylenetetramine;  
TEPA - Tetraethylenepentamine; PEHA – Pentaethylenehexamine

Table 3

5 Nucleic acid recovery from whole MTB aided by an ethylene-amine and various metal salts

No.	Additives	Ct	Std Dev (n=3)
1	None	36.74	0.52
2	8mM MgCl <sub>2</sub>	30.78	0.41
3	16mM TETA	28.22	0.05
4	8mM Mg(OAC) <sub>2</sub> + 16mM TETA*	28.45	0.26
5	23mM Mg(OAC) <sub>2</sub> + 16mM TETA	28.78	0.29
6	8mM Mn(OAC) <sub>2</sub> + 16mM TETA	31.07	0.15
7	23mM Mn(OAC) <sub>2</sub> + 16mM TETA	32.65	0.11

No.	Additives	Ct	Std Dev (n=3)
1	None	34.73	0.36
2	8mM MgCl <sub>2</sub>	27.17	0.20
3	16mM TEPA	31.50	0.80
4	8mM Mg(OAC) <sub>2</sub> + 16mM TEPA	26.95	0.23
5	23mM Mg(OAC) <sub>2</sub> + 16mM TEPA	26.82	0.27
6	8mM Mn(OAC) <sub>2</sub> + 16mM TEPA	26.85	0.44
7	23mM Mn(OAC) <sub>2</sub> + 16mM TEPA	30.50	0.65

\* TETA – Triethylenetetramine

Table 4

*Cell-free MTB nucleic acid recovery aided by an ethylene-amine and metal salts*

No.	Additives	Ct	Std Dev (n=3)
1	None	42.86	0.55
2	8mM MgCl <sub>2</sub>	35.38	0.22
3	16mM TEPA*	39.10	3.77
4	8mM Mg(OAC) <sub>2</sub> + 16mM TEPA	35.57	0.63
5	23mM Mg(OAC) <sub>2</sub> + 16mM TEPA	35.52	0.58
6	8mM Mn(OAC) <sub>2</sub> + 16mM TEPA	35.78	0.32
7	23mM Mn(OAC) <sub>2</sub> + 16mM TEPA	39.70	0.76

No.	Additives	Ct	Std Dev (n=3)
1	None	42.99	1.33
2	8mM MgCl <sub>2</sub>	35.15	0.12
3	23mM MgCl <sub>2</sub>	35.78	0.72
4	8mM Mg(OAC) <sub>2</sub>	35.46	0.20
5	23mM Mg(OAC) <sub>2</sub>	37.17	0.48
6	16mM TETA	35.15	0.19
7	8mM MgCl <sub>2</sub> + 16mM TETA	34.68	0.14
8	23mM MgCl <sub>2</sub> + 16mM TETA	34.47	0.19
9	8mM Mg(OAC) <sub>2</sub> + 16mM TETA	34.66	0.29
10	23mM Mg(OAC) <sub>2</sub> + 16mM TETA	34.65	0.38

\* TETA – Triethylenetetramine

The results demonstrate that the ethylene-amine compounds improve the recovery of

5 nucleic acids using solid supports such as magnetic glass particles. The improvement is further enhanced by the presence of metal salts, for example, magnesium or manganese salts, such as chloride or acetate salts.

While the invention has been described in detail with reference to specific examples, it will be apparent to one skilled in the art that various modifications can be made within the

10 scope of this invention. Thus the scope of the invention should not be limited by the examples described herein, but by the claims presented below.

## CLAIMS

1. A method of separating nucleic acids from a sample solution containing nucleic acids, comprising

5 a. contacting the sample solution with a solid phase capable of binding nucleic acids and a binding mixture comprising an ethylene-amine compound;

b. incubating the sample solution containing the solid phase under the conditions in which the nucleic acids may bind to the solid phase; and

c. separating the solid phase from the solution.

10

2. The method of claim 1, further comprising washing the solid-phase-bound nucleic acids.

15 3. The method of claim 1, further comprising eluting nucleic acids from the solid phase.

4. The method of claim 1, wherein said sample solution is obtained by the lysis of cells.

20 5. The method of claim 4, wherein said sample solution is obtained by the lysis of Gram-positive bacteria selected from a group consisting of *Bacillus*, *Clostridium*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Mycobacterium*, and combinations thereof.

25 6. The method of claim 1, wherein the binding mixture in step a further comprises metal ions.

7. The method of claim 6, wherein the binding mixture in step a contains magnesium or manganese ions.

30 8. The method of claim 1 wherein the binding mixture in step a further comprises a hydroxide of an alkali metal and a detergent.

9. The method of claim 8 wherein the binding mixture in step a comprises a mixture of equal volumes of Solution 1 (50mM NaOH, 1% Triton X-100, 1mM EDTA, 0.05% NaN<sub>3</sub>, pH 12+) and Solution 2 (10-65mM ethylene-amine, 200mM Tris, 5-25mM MgCl<sub>2</sub>, 0.05% NaN<sub>3</sub>, pH 7.5.)

5

10. The method of claim 1, wherein the solid phase capable of binding nucleic acid comprises particles having a magnetic core and a silica-containing outer layer.

11. A reaction mixture for separating nucleic acids from a sample using a solid phase, the mixture comprising: a solid phase capable of binding nucleic acids and an ethylene-amine compound.

12. The reaction mixture of claim 11 further comprising a hydroxide of an alkali metal and a detergent.

15

13. The reaction mixture of claim 11 further comprising metal ions.

14. The reaction mixture of claim 13, comprising magnesium or manganese ions.

20 15. The reaction mixture of claim 11, wherein the solid phase capable of binding nucleic acid comprises particles having a magnetic core and a silica-containing outer layer.

16. A kit for separating nucleic acids from a sample using a solid phase, the kit comprising: a solid phase capable of binding nucleic acids and an ethylene-amine compound.

25

17. The kit of claim 16, further comprising one or more of a lysis reagent, a neutralization reagent, a wash reagent and an elution reagent.

30 18. The kit of claim 16, wherein the solid phase capable of binding nucleic acid comprises particles having a magnetic core and a silica-containing outer layer.

19. The kit of claim 16, wherein the lysis reagent contains a hydroxide of an alkali metal and a detergent, a neutralization reagent contains an ethylene-amine compound, magnesium or manganese ions and a buffer.

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2011/000013

**A. CLASSIFICATION OF SUBJECT MATTER**

INV. C12N15/10 C12Q1/68 C12N1/06  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/013155 A2 (CYCLOPS GENOME SCIENCES LTD [GB]; GOLDSBOROUGH ANDREW SIMON [FR]) 12 February 2004 (2004-02-12) page 11, paragraph 3 - page 12, paragraph 1; claims 26-44; examples 1, 8, 10-12, 16-18 -----	11-19
X	EP 1 983 051 A2 (ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]) 22 October 2008 (2008-10-22) paragraphs [0022] - [0066] -----	1-9
X	WO 99/58644 A1 (UNIV HAWAII [US]; NAN GUO LING [US]; NAGAI CHIFUMI [US]) 18 November 1999 (1999-11-18) page 7, line 5 - page 22, line 27 ----- -/-	1-9



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 March 2011

Date of mailing of the international search report

04/04/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Westphal-Daniel, K

## INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/000013

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2006/003357 A1 (MCKERNAN KEVIN [US] ET AL) 5 January 2006 (2006-01-05) paragraphs [0016] - [0055] -----	1-9
X	US 6 534 262 B1 (MCKERNAN KEVIN [US] ET AL) 18 March 2003 (2003-03-18) column 5, line 31 - column 16, line 2 -----	1-9
X	WO 2004/042058 A2 (INVITEK GES FUER BIOTECHNIK & [DE]; HILLEBRAND TIMO [DE]; BENDZKO PETE) 21 May 2004 (2004-05-21) page 5, paragraph 4 - page 9, paragraph 3; claims 1-28 -----	1-9
X	WO 2008/119488 A1 (ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]; WILL STEPHEN GORD) 9 October 2008 (2008-10-09) page 4, lines 8-16; claims 14,16; example 2 paragraphs [0III], [00IV] -----	11,16
X,P	EP 2 157 181 A1 (AGOWA GES FUER MOLEKULARBIOLOG [DE]) 24 February 2010 (2010-02-24) paragraph [0032]; claims 1,7,8,13; examples 5-9 -----	1-4,11
A	US 6 255 477 B1 (KLEIBER JOERG [DE] ET AL) 3 July 2001 (2001-07-03) cited in the application column 2, line 0 - column 8, line 56 -----	1-19
A	EP 1 577 389 A2 (ROCHE DIAGNOSTICS GMBH [DE]) 21 September 2005 (2005-09-21) cited in the application paragraphs [0001] - [0054] -----	1-19

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/EP2011/000013

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2004013155	A2	12-02-2004	AU	2003281862 A1		23-02-2004
			EP	1525309 A2		27-04-2005
			JP	2005538116 T		15-12-2005
			US	2006147918 A1		06-07-2006
EP 1983051	A2	22-10-2008	CA	2629589 A1		20-10-2008
			CN	101289661 A		22-10-2008
			JP	2008263982 A		06-11-2008
			US	2008319182 A1		25-12-2008
WO 9958644	A1	18-11-1999	AU	3902799 A		29-11-1999
US 2006003357	A1	05-01-2006		NONE		
US 6534262	B1	18-03-2003	US	2003235839 A1		25-12-2003
			US	2010121044 A1		13-05-2010
WO 2004042058	A2	21-05-2004	AU	2003291931 A1		07-06-2004
			EP	1560926 A2		10-08-2005
			US	2006160085 A1		20-07-2006
WO 2008119488	A1	09-10-2008	CA	2681584 A1		09-10-2008
			EP	2132549 A1		16-12-2009
			JP	2010522544 T		08-07-2010
			US	2009081661 A1		26-03-2009
EP 2157181	A1	24-02-2010	WO	2010018200 A1		18-02-2010
US 6255477	B1	03-07-2001	AT	301665 T		15-08-2005
			AT	368109 T		15-08-2007
			AT	239031 T		15-05-2003
			AU	707115 B2		01-07-1999
			CA	2223821 A1		27-12-1996
			CA	2440504 A1		25-02-2005
			CA	2605671 A1		27-12-1996
			CA	2607563 A1		27-12-1996
			CN	1439646 A		03-09-2003
			CN	1192217 A		02-09-1998
			CN	1891833 A		10-01-2007
			CN	1974781 A		06-06-2007
			DE	19520398 A1		12-12-1996
			DE	19537985 A1		17-04-1997
			DE	59610405 D1		05-06-2003
			DE	59611258 D1		15-09-2005
			DK	1281714 T3		19-12-2005
			DK	1577389 T3		26-11-2007
US 6255477	B1		DK	0837871 T3		25-08-2003
			WO	9641811 A1		27-12-1996
			EP	1281714 A1		05-02-2003
			EP	1602724 A1		07-12-2005
			EP	1577389 A2		21-09-2005
			EP	0837871 A1		29-04-1998
			ES	2247236 T3		01-03-2006
			ES	2290803 T3		16-02-2008
			ES	2197947 T3		16-01-2004
			HK	1051048 A1		28-10-2005
			HK	1075065 A1		28-09-2007

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/000013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP 3950478 B2	01-08-2007
		JP 11509364 T	17-08-1999
		JP 4456046 B2	28-04-2010
		JP 2006075160 A	23-03-2006
		NO 975772 A	06-02-1998
		NZ 311648 A	30-08-1999
		US 2003135038 A1	17-07-2003
		US 2002137920 A1	26-09-2002
EP 1577389	A2 21-09-2005	AT 301665 T	15-08-2005
		AT 368109 T	15-08-2007
		AT 239031 T	15-05-2003
		AU 707115 B2	01-07-1999
		CA 2223821 A1	27-12-1996
		CA 2440504 A1	25-02-2005
		CA 2605671 A1	27-12-1996
		CA 2607563 A1	27-12-1996
		CN 1439646 A	03-09-2003
		CN 1192217 A	02-09-1998
		CN 1891833 A	10-01-2007
		CN 1974781 A	06-06-2007
		DE 19520398 A1	12-12-1996
		DE 19537985 A1	17-04-1997
		DE 59610405 D1	05-06-2003
		DE 59611258 D1	15-09-2005
		DK 1281714 T3	19-12-2005
		DK 1577389 T3	26-11-2007
		DK 0837871 T3	25-08-2003
		WO 9641811 A1	27-12-1996
		EP 1281714 A1	05-02-2003
		EP 1602724 A1	07-12-2005
		EP 0837871 A1	29-04-1998
		ES 2247236 T3	01-03-2006
		ES 2290803 T3	16-02-2008
		ES 2197947 T3	16-01-2004
EP 1577389	A2	HK 1051048 A1	28-10-2005
		HK 1075065 A1	28-09-2007
		JP 3950478 B2	01-08-2007
		JP 11509364 T	17-08-1999
		JP 4456046 B2	28-04-2010
		JP 2006075160 A	23-03-2006
		NO 975772 A	06-02-1998
		NZ 311648 A	30-08-1999
		US 2003135038 A1	17-07-2003
		US 2002137920 A1	26-09-2002
		US 6255477 B1	03-07-2001